Who are Cinqair's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fasenra, Nucala, Fasenra®, Mepolizumab Injection [Nucala], Nucala, Liquid mepolizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/reslizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Cinqair — Competitive Intelligence Brief

Cinqair (RESLIZUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-5 Antagonist [EPC]. Area: Respiratory.

marketed Interleukin-5 Antagonist [EPC] Interleukin-5 Respiratory Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Cinqair (RESLIZUMAB) — Teva Respiratory Llc. Cinqair works by blocking the action of interleukin-5, a protein that promotes the production of eosinophils, which contribute to inflammation in the airways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cinqair TARGET	RESLIZUMAB	Teva Respiratory Llc	marketed	Interleukin-5 Antagonist [EPC]	Interleukin-5	2016-01-01
Fasenra	BENRALIZUMAB	AstraZeneca	marketed	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	Interleukin-5 receptor subunit alpha	2017-01-01
Nucala	MEPOLIZUMAB	GSK	marketed	Interleukin-5 Antagonist [EPC]	Interleukin-5	2015-01-01
Fasenra®	Fasenra®	AstraZeneca	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5Rα (interleukin-5 receptor alpha)
Mepolizumab Injection [Nucala]	Mepolizumab Injection [Nucala]	KU Leuven	marketed	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Nucala	Nucala	Mayo Clinic	marketed		Interleukin-5
Liquid mepolizumab	Liquid mepolizumab	GlaxoSmithKline	phase 3	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-5 Antagonist [EPC] class)

GSK · 1 drug in this class
Teva Respiratory Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cinqair — Competitive Intelligence Brief. https://druglandscape.com/ci/reslizumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab